


Remarks

Claims 1 to 15 have been cancelled herein. New Claims 16 to 22 have been added. Support for the new claims can be found throughout the specification and in the originally filed claims. For example, the composition of Claim 16 is discussed on pages 4, 5, and 8. The processes claimed in Claims 17 to 22 are discussed in the Examples and on pages 5 to 8. Cell lines are discussed on page 6, secretase inhibitors are discussed on page 7 and example 1, alpha secretase is discussed on page 7.

The Specification has been amended to add the statement of the related cases of the current application on page 1.

An Information Disclosure Statement for the instant application is filed with this Preliminary Amendment.

Respectfully submitted,



Mark J. Stewart, Ph.D.
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
P.O. Box 6288
Indianapolis, Indiana 46206-6288

August 23, 2006

Rev. 6/05